Randomized Trialhigh evidence
Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes.
The New England journal of medicine·August 7, 2025·PMID 40470996
Why it mattersIt provides the first randomized evidence on simultaneous initiation of an SGLT2 inhibitor and a nonsteroidal mineralocorticoid receptor antagonist, addressing a common clinical scenario where both drug classes are indicated.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled